CLASS ACTION UPDATE for IRTC, QS and AZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / February 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

IRTC Shareholders Click Here: https://www.zlk.com/pslra-1/irhythm-technologies-inc-loss-form?prid=13034&wire=1
QS Shareholders Click Here: https://www.zlk.com/pslra-1/quantumscape-corporation-f-k-a-kensington-capital-acquisition-corp-loss-submission-form?prid=13034&wire=1
AZN Shareholders Click Here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13034&wire=1

* ADDITIONAL INFORMATION BELOW *

iRhythm Technologies, Inc. (NASDAQ:IRTC)

IRTC Lawsuit on behalf of: investors who purchased August 4, 2020 - January 28, 2021
Lead Plaintiff Deadline : April 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/irhythm-technologies-inc-loss-form?prid=13034&wire=1

According to the filed complaint, during the class period, iRhythm Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) iRhythm's business would suffer as a result of the CMS' rulemaking; (2) reimbursement rates would in fact plummet; (3) a lack of national pricing in the CMS rule and fee schedule would cause uncertainty and weakness in the Company's business; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times

QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. (NYSE:QS)

QS Lawsuit on behalf of: investors who purchased November 27, 2020 - December 31, 2020
Lead Plaintiff Deadline : March 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/quantumscape-corporation-f-k-a-kensington-capital-acquisition-corp-loss-submission-form?prid=13034&wire=1

According to the filed complaint, during the class period, QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) that the Company is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Astrazeneca Plc (NYSE:AZN)

AZN Lawsuit on behalf of: investors who purchased May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=13034&wire=1

According to the filed complaint, during the class period, Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:
https://www.accesswire.com/630904/CLASS-ACTION-UPDATE-for-IRTC-QS-and-AZN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders